Back to top
more

BeiGene, Ltd. (BGNE)

(Delayed Data from NSDQ)

$343.09 USD

343.09
328,796

+1.64 (0.48%)

Updated Aug 4, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.60%
2Buy19.21%
3Hold10.85%
4Sell6.62%
5Strong Sell3.32%
S&P50011.33%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 19% (205 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for BGNE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for BeiGene, Ltd. falls in the month of December.

All items in Millions except Per Share data.

12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Assets          
Cash & Equivalents 4,651 983 1,796 838 368
Receivables 60 71 50 29 0
Notes Receivable 0 0 0 0 0
Inventories 89 29 16 11 0
Other Current Assets 160 90 82 36 6
Total Current Assets 4,961 1,173 1,944 914 374
Net Property & Equipment 358 242 157 63 26
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 66 38 30 8 1
Intangibles 5 6 52 20 0
Deposits & Other Assets 121 71 67 43 5
Total Assets 5,601 1,612 2,250 1,046 406
Liabilities & Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Notes Payable 335 0 0 0 0
Accounts Payable 232 122 113 70 12
Current Portion Long-Term Debt 0 0 9 9 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 346 164 100 50 22
Income Taxes Payable 20 13 6 9 1
Other Current Liabilities 128 0 18 12 0
Total Current Liabilities 1,075 310 246 150 35
Mortgages 0 0 0 0 0
Deferred Taxes/Income 11 11 21 25 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 184 241 190 155 17
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 432 47 39 32 1
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 1,732 634 496 362 53
Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 7,415 2,926 2,745 1,001 591
Retained Earnings -3,553 -1,956 -1,007 -331 -237
Other Equity 7 8 16 14 -1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 3,869 978 1,754 684 353
Total Liabilities & Shareholder's Equity 5,601 1,612 2,250 1,046 406
Total Common Equity 3,869 978 1,754 684 353
Shares Outstanding 91.10 61.60 59.40 45.50 31.50
Book Value Per Share 42.47 15.88 29.52 15.04 11.20

Fiscal Year End for BeiGene, Ltd. falls in the month of December.

All items in Millions except Per Share data.

6/30/2021 3/31/2021 12/31/2020 9/30/2020 6/30/2020
Assets          
Cash & Equivalents NA 4,813 4,651 4,719 3,153
Receivables NA 84 60 60 62
Notes Receivable NA 0 0 0 0
Inventories NA 73 89 36 33
Other Current Assets NA 171 160 151 144
Total Current Assets NA 5,141 4,961 4,966 3,392
Net Property & Equipment NA 374 358 291 258
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 78 66 48 40
Intangibles NA 5 5 5 5
Deposits & Other Assets NA 136 121 168 117
Total Assets NA 5,821 5,601 5,566 3,903
Liabilities & Shareholders Equity 6/30/2021 3/31/2021 12/31/2020 9/30/2020 6/30/2020
Notes Payable NA 405 335 50 26
Accounts Payable NA 147 232 146 157
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 312 346 279 208
Income Taxes Payable NA 27 20 9 10
Other Current Liabilities NA 207 128 147 137
Total Current Liabilities NA 1,113 1,075 646 551
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 89 11 12 11
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 193 184 152 292
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 432 432 471
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 1,817 1,732 1,270 1,357
Shareholders Equity 6/30/2021 3/31/2021 12/31/2020 9/30/2020 6/30/2020
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 7,487 7,415 7,368 5,200
Retained Earnings NA -3,486 -3,553 -3,080 -2,655
Other Equity NA 3 7 9 1
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 4,004 3,869 4,297 2,546
Total Liabilities & Shareholder's Equity NA 5,821 5,601 5,566 3,903
Total Common Equity 0 4,004 3,869 4,297 2,546
Shares Outstanding 92.20 91.70 91.10 90.60 78.00
Book Value Per Share 0.00 43.66 42.47 47.42 32.65